Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...

ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus ...

The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

If you have advanced Parkinson’s disease (PD), you may hear about a treatment option called Vyalev (foscarbidopa/foslevodopa). It was approved by the FDA in 2024 ...